Aitmei

Aitmei is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, dedicated to developing next-generation treatments for metabolic disorders. The company's primary focus is on multi-target agonists, including GLP-1, GIP, and Glucagon receptor pathways, aimed at addressing obesity, type 2 diabetes, and metabolic-associated steatohepatitis (MASH). Their lead candidate, ATM-011, is a long-acting triple agonist currently in clinical development for weight management and glycemic control. Additionally, Aitmei is advancing ATM-022, an oral small molecule GLP-1 receptor agonist designed to offer a more convenient dosing alternative to injectables. The company leverages a deep understanding of metabolic signaling to optimize the potency and safety profiles of its candidates. Backed by prominent venture capital firms, Aitmei is positioned as a significant player in the rapidly evolving landscape of incretin-based therapies.